e-med-isral-ribbon

Orlistat Helpful for Obese Type 2 Diabetics

June 27, 2002 —

Orlistat (Xenical) is beneficial for obese type 2 diabetic patients, according to results of a randomized, placebo-controlled trial reported in the July issue of Diabetes Care.

 However, the reduction in HbA1c was less than 0.5%, and lifestyle modification, diet, and exercise still need to be the cornerstone of therapy.

Despite significantly more adverse effects in the orlistat group, the withdrawal rate was higher in the placebo group, suggesting a perceived benefit from being on the medication. “The results of this study show that the addition of orlistat plus a reduced calorie diet to existing metformin therapy can benefit patients by helping lower body weight and serum glucose levels,” lead author John M. Miles, MD, from the Mayo Clinic in Rochester, Minnesota, says in a news release.

 “The combination of Xenical and metformin had a positive impact on many cardiovascular risk factors, which are among the most common and potentially serious risks associated with type 2 diabetes.” This study enrolled 516 patients at 34 centers in the U.S. and six centers in Canada who were receiving metformin, 1,000 to 2,550 mg/day for at least six weeks, or a stable dose of sulfonylureas for 12 weeks before study entry in addition to metformin. Subjects were randomized to receive either orlistat, 120 mg three times daily, or placebo in addition to a reduced-calorie diet. Of the original study group, 311 patients completed one year of treatment.

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים

© ‫ אי-מד שיווק רפואי בע”מ
 כל הזכויות שמורות
09-765-8233 

 

הנך גולש/ת באתר כאורח/ת.

במידה והנך מנוי את/ה מוזמן/ת לבצע כניסה מזוהה וליהנות מגישה לכל התכנים המיועדים למנויים
עדיין לא מנוי/ה ונמנה/ת על הצוות הרפואי? מוזמן/ת לבצע הרשמה כאן
להרשמה לאתר
להמשך גלישה כאורח סגור חלון זה